Abstract:Aim: To investigate the expression level of plasma vascular endothelial growth factor (P-VEGF) in patients with hepatocellular carcinoma (HCC) and its relationship with the clinicopathologic characteristics, and to examine the changes of P-VEGF in the course of transcatheter arterial chemoembolization (TACE). Methods: Peripheral blood samples were taken from 45 HCC patients before and 1, 3, 7 d, and 1 mo after TACE. Plasma VEGF level was measured with the quantitative sandwich enzyme-linked immunosorbent assay (ELISA). Twenty patients with benign liver lesions and 17 healthy control subjects were also included in this study. Results: Plasma VEGF levels in HCC patients were significantly elevated as compared to those in patients with benign liver lesions (P = 0.006) and in the normal controls (P = 0.003). Significant differences were observed when P-VEGF was categorized by tumor size (P = 0.006), portal vein thrombosis (P = 0.011), distant metastasis (P = 0.017), arterial-portal vein shunting (P = 0.026), and International Union Against Cancer (UICC) TNM stage (P = 0.044). There was no correlation between plasma level of VEGF and the level of alpha fetoprotein (alpha-FP) (r = 0.068, P = 0.658) and weakly correlated with the number of platelets (r = 0.312, P = 0.038). P-VEGF levels increased significantly and reached the peak value on the first day after TACE, and then decreased gradually. The change rate of P-VEGF concentration (one month post-TACE/pre-TACEX100%) was correlated with the retention rate of lipiodol oil (r s = 0.494, P = 0.001) and the tumor volume change (r s = 0.340, P = 0.034). The patients who achieved a partial or complete response to TACE therapy showed significantly less pre-treatment P-VEGF than those nonresponders (P = 0.025). A high pre-therapeutic P-VEGF level was associated with poor response to treatment (P = 0.018). Conclusion: A high pre-treatment P-VEGF level is a useful marker for tumor progression, especially for vascular invasion. TACE increases the level of P-VEGF only temporarily which may be associated with tumor ischemia. P-VEGF may be useful in predicting treatment response, monitoring disease course after TACE and judging the effect of different TACE regimens.

Expression and Significance of VEGF and MVD in Hepatocellular Carcinoma Patients Received Preop-Erative Transcatheter Arterial Embolization

Effect of transcatheter arterial chemoembolization on angiogenesis and expression of vascular endothelial growth factor in cervical squamous cell carcinoma

Expression of Human Vascular Endothelial Growth Factor in Ampullary Carcinoma and Its Significance

Intratumoral microvessel density and expression of vascular endothelial growth factor in hepatocellular carcinoma after chemoembolization

Expression of VEGF,integrin-αV and MVD in Viable Residual Tumor Tissues from Large Hepatocellular Carcinoma after TACE

Relationship of HDGF or VEGF expression with hepatocellular carcinoma angiogenesis:report of 108 cases

Expression of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor level

Association Between Vascular Endothelial Growth Factor and Metastasis after Transcatheter Arterial Chemoembolization in Patients with Hepatocellular Carcinoma

Effects of TACE on expressions of HIF-1α and VEGF and their correlation with neovascularization in rabbit VX2 liver neoplasms

Vascular endothelial growth factor receptor-2 and its phosphorylated state in cancerous and peri-cancerous tissues of hepatocellular carcinoma after transcatheter arterial chemoembolization

Expression and Clinical Significance of CD146 and VEGF in Hepatocellular Carcinoma

Prognostic Significance of Vascular Endothelial Growth Factor Expression and Microvessel Density in Carcinoma of Ampulla of Vater.

High Expression of VEGF in Peritumoral Liver Tissue Is Associated With Poor Survival After Curative Resection of Hepatocellular Carcinoma

Application of polymorphisms of vascular endothelial growth factor in evaluating the prognosis of hepatocellular carcinoma patients after transcatheter arterial chemoembolization treatment

Experimental Study on Early Effect of Plasma Vascular Endothelial Growth Factor in Rabbits with Hepatic VX2 Tumors after Transcatheter Arterial Chemoembolization

Impact of Serum Vascular Endothelial Growth Factor on Prognosis in Patients with Unresectable Hepatocellular Carcinoma after Transarterial Chemoembolization

Prospective Evaluation of the Value of Vascular Endothelial Growth Factor Messenger RNA for Prediction of Recurrence and Metastasis of Hepatocellular Carcinoma Following Liver Transplantation

Serum and Tissue Vascular Endothelial Growth Factor Predicts Prognosis in Hepatocellular Carcinoma Patients after Partial Liver Resection.

HIGH- THROUGHPUT TISSUE MICROARRAY ANALYSIS EXPRESSION OF VASCULAR ENDOTHELIAL GROWTH FACTIOR IN PRIMARY LIVER CANCER AND ITS RELATIONSHIP WITH PROGNOSIS

[Prognostic Significance of Serum Level of Vascular Endothelial Growth Factor Receptor-2 in Hepatocellular Carcinoma Patients after Transcatheter Arterial Chemoembolization].

[Expression of Vascular Endothelial Growth Factor Correlates with Invasion and Metastasis of Hepatocellular Carcinoma].